March 17, 2022
Complement System TCC and C4d ELISAs Now Available
ALPCO is pleased to announce the availability of two new immunoassays to measure complement system activation, the Complement C4d ELISA and the Terminal Complement Complex (TCC) ELISA.The complement system plays an essential role in acute and chronic inflammation, in immune response to infections, and in autoimmune disease. Complement pathway activation has become an important tool for drug development and clinical research programs.
Why measure C4d? The Complement System is made up of three pathways - Classical, Lectin/MBL, and Alternative. The Classical and Lectin Pathways meet early in the immune response cascade, and share C4d as an activation product. C4d is increasingly recognized as a potential biomarker for diseases where antibodies can cause tissue damage, such as systemic autoimmune diseases. C4d complement testing can help monitor disease activity, allow for testing of complement drugs, and help verify the effect of certain treatments. The Complement C4d ELISA targets a unique neoepitope to eliminate cross-reactivity issues and tests for both A and B genetic variants.
Download the C4d datasheet
Why measure TCC? Terminal Complement Complex (TCC, also known as sC5b-9) is a byproduct of Membrane Attack Complex formation and shows if there was any activation at all within the complement system. The TCC ELISA is therefore useful as an overall look at complement system activity to understand whether or not the innate immune system was triggered, regardless of pathway. TCC has been used for over 30 years as a complement activity biomarker in research and drug development.
Download the TCC datasheet
To learn more about the complement system and related immunoassays, please visit www.alpco.com/complement-system.
